[go: up one dir, main page]

MX2012007997A - Preparacion solida recubierta. - Google Patents

Preparacion solida recubierta.

Info

Publication number
MX2012007997A
MX2012007997A MX2012007997A MX2012007997A MX2012007997A MX 2012007997 A MX2012007997 A MX 2012007997A MX 2012007997 A MX2012007997 A MX 2012007997A MX 2012007997 A MX2012007997 A MX 2012007997A MX 2012007997 A MX2012007997 A MX 2012007997A
Authority
MX
Mexico
Prior art keywords
solid preparation
montelukast
coated solid
coated
acceptable salt
Prior art date
Application number
MX2012007997A
Other languages
English (en)
Other versions
MX344141B (es
Inventor
Yasuhide Horiuchi
Yuki Fujisaki
Ryoji Yoshii
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2012007997A publication Critical patent/MX2012007997A/es
Publication of MX344141B publication Critical patent/MX344141B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un objetivo de la presente invención es proporcionar una preparación sólida recubierta que contiene montelukast, que se puede aplicar a un empaque de una dosis, en donde la estabilidad a la humedad de montelukast o una sal farmacológicamente aceptable del mismo contenida en el mismo se mantiene incluso cuando la preparación se desempaca. La presente invención proporciona una preparación sólida recubierta que contiene como un ingrediente activo montelukast o una sal farmacológicamente aceptable del mismo y que está recubierta con una capa de recubrimiento que comprende alcohol polivinílico y arcilla de expansión, en donde la relación en masa del alcohol polivinílico descrito en lo anterior respecto a la arcilla de expansión descrito en lo anterior en la capa de recubrimiento descrita en lo anterior es de 8:2 a 3:7.+.
MX2012007997A 2010-02-26 2011-02-25 Preparacion solida recubierta. MX344141B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010042066 2010-02-26
PCT/JP2011/054256 WO2011105539A1 (ja) 2010-02-26 2011-02-25 被覆固形製剤

Publications (2)

Publication Number Publication Date
MX2012007997A true MX2012007997A (es) 2012-08-23
MX344141B MX344141B (es) 2016-12-07

Family

ID=44506936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007997A MX344141B (es) 2010-02-26 2011-02-25 Preparacion solida recubierta.

Country Status (14)

Country Link
US (1) US8658208B2 (es)
EP (1) EP2540298B1 (es)
JP (1) JP5761018B2 (es)
KR (1) KR101445671B1 (es)
CN (1) CN102762205B (es)
BR (1) BR112012015923A2 (es)
CA (1) CA2785694C (es)
ES (1) ES2552628T3 (es)
HU (1) HUE026633T2 (es)
MX (1) MX344141B (es)
PL (1) PL2540298T3 (es)
SI (1) SI2540298T1 (es)
TW (1) TWI480067B (es)
WO (1) WO2011105539A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI438012B (zh) 2008-12-25 2014-05-21 Toray Industries 固態製劑用之塗覆劑及使用其之固態製劑
GB2509460A (en) * 2011-09-29 2014-07-02 Meditop Gy Gyszeripari Kft Coating Composition
KR101278572B1 (ko) * 2011-10-18 2013-06-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
CN102973532A (zh) * 2012-12-28 2013-03-20 南京瑞尔医药有限公司 一种稳定的孟鲁司特钠片剂及制备方法
TWI658842B (zh) 2014-03-31 2019-05-11 日商東麗股份有限公司 固體製劑用之被覆劑以及由其所形成之被膜及被覆固體製劑
JP7194524B2 (ja) * 2018-06-25 2022-12-22 日本酢ビ・ポバール株式会社 コーティング組成物並びに経口固形剤及びその製造方法
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
WO2020055455A1 (en) * 2018-09-14 2020-03-19 Cedars-Sinai Medical Center Targeted nanoparticles for diagnosing, detecting, and treating cancer
EP4527411A1 (en) * 2022-05-18 2025-03-26 Towa Pharmaceutical Co., Ltd. Membrane-forming composition, membrane-like composition, and use of same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5157815A (en) * 1974-11-14 1976-05-20 Sumitomo Chemical Co Toijono seizohoho
JPS5942325A (ja) * 1982-09-03 1984-03-08 Dai Ichi Seiyaku Co Ltd コ−テイング用組成物及びコ−テイング製剤
JPS61186313A (ja) 1985-02-12 1986-08-20 Dainippon Pharmaceut Co Ltd バルプロ酸ナトリウム製剤
JP2803179B2 (ja) * 1989-06-28 1998-09-24 東洋紡績株式会社 被覆プラスチックフイルム
JPH03120211A (ja) 1989-10-04 1991-05-22 Earth Chem Corp Ltd 粒状カルニチン製剤
AU662429B2 (en) * 1992-07-29 1995-08-31 Sumitomo Chemical Company, Limited Gas barrier resin composition and its film and process for producing the same
DE670160T1 (de) 1994-03-01 1996-03-14 Gergely, Gerhard, Dr., Wien Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
WO2002067906A1 (de) 2001-02-27 2002-09-06 Röhm GmbH & Co. KG Überzugs- und bindemittel für arzneimittelformulierungen mit verbesserter lagerstabilität
NL1018607C2 (nl) * 2001-07-20 2003-01-21 Friesland Brands Bv Vochtbarrière in voedingsmiddelen.
EP1678139B1 (en) 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
BRPI0506610A (pt) * 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
JP2007145717A (ja) 2005-11-24 2007-06-14 Eisai R & D Management Co Ltd フィルムコーティング製剤
ES2277563B1 (es) * 2005-12-29 2008-06-16 Nanobiomatters, S.L. Procedimiento de fabricacion de materiales nanocompuestos para aplicaciones multisectoriales.
EP1803457A1 (en) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
RS51330B (sr) * 2006-02-09 2011-02-28 Teva Pharmaceutical Industries Ltd. Stabilne farmaceutske formulacije montelukast natrijuma
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
US20090124657A1 (en) * 2007-08-14 2009-05-14 Ramesh Kappala Pharmaceutical compositions comprising montelukast
TWI438012B (zh) * 2008-12-25 2014-05-21 Toray Industries 固態製劑用之塗覆劑及使用其之固態製劑
SI2412369T1 (sl) 2009-03-27 2016-12-30 Torray Industries, Inc. Obloženi trdni pripravek

Also Published As

Publication number Publication date
CN102762205B (zh) 2014-03-12
WO2011105539A1 (ja) 2011-09-01
BR112012015923A2 (pt) 2020-09-08
CN102762205A (zh) 2012-10-31
TW201136618A (en) 2011-11-01
KR101445671B1 (ko) 2014-09-29
TWI480067B (zh) 2015-04-11
ES2552628T3 (es) 2015-12-01
SI2540298T1 (sl) 2016-02-29
EP2540298A1 (en) 2013-01-02
KR20120098877A (ko) 2012-09-05
US20120321677A1 (en) 2012-12-20
CA2785694A1 (en) 2011-09-01
HUE026633T2 (en) 2016-06-28
CA2785694C (en) 2013-12-17
JPWO2011105539A1 (ja) 2013-06-20
MX344141B (es) 2016-12-07
EP2540298B1 (en) 2015-11-04
JP5761018B2 (ja) 2015-08-12
PL2540298T3 (pl) 2016-04-29
EP2540298A4 (en) 2014-04-09
US8658208B2 (en) 2014-02-25

Similar Documents

Publication Publication Date Title
MX344141B (es) Preparacion solida recubierta.
EA201291028A1 (ru) Полипропиленовая композиция, подходящая для нанесения покрытий экструзией
DK2282994T3 (da) 3-aminocarbazolforbindelse, farmaceutisk sammensætning indeholdende forbindelsen samt fremstillingsmetode derfor
LT3216448T (lt) Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sisteminio poveikio veikliuosius agentus, būdai ir jų panaudojimas
WO2011049309A3 (ko) 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2013510216A5 (es)
WO2013130898A3 (en) Stabilizing agents and methods of use thereof
WO2011155793A3 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
WO2012048176A3 (en) Attachment and retention formulations for biologically active organic compounds
LT2658844T (lt) Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
MX344324B (es) Endoprotesis que contiene un recubrimiento de substancia activa.
WO2011140446A3 (en) Pharmaceutical formulations
EP2496083A4 (en) NICOTINE-CONTAINING FORMULATION
WO2009060952A1 (ja) 新規製剤
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2014149176A3 (en) Use of chromobacterium substugae formulations, compositions and compounds to modulate cornworm rootworm larvae infestation
CA2750209A1 (en) Coated solid preparations of valproic acid
WO2011139728A3 (en) Packaging for electrochemically active materials, devices made therefrom, and methods of making the same
WO2014166836A8 (en) Growth hormone compound formulation
EP2452678A3 (en) Pulsatile-release pharmaceutical formulation of dexlansoprazole
IL206739A (en) An injectable drug containing silitol as an active substance
MX336924B (es) Formulacion inyectable de una lactona macrociclica y levamisol.

Legal Events

Date Code Title Description
FG Grant or registration